Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profile
A. Burban, C. Tessier, M. Pinglaut, J. Guyon, J. Galvis, B. Dartigues, M. Toujas, M. Larroquette, H. A. Luchman, S. Weiss, N. Nicot, B. Klink, M. Nikolski, L. Brisson, T. Mathivet, , A. Sharanek
This study shows that mubritinib targets brain tumour stem cells by inhibiting complex I of the electron transport chain, delays glioblastoma tumourigenesis, and is safe in mice.
bioRxiv · Jan 15, 2024Cancer Biology